COVID-19 drug practices risk antimicrobial resistance evolution

Ebrahim Afshinnekoo (1) , Chandrima Bhattacharya (1) , Ana Burguete-García (2) , Eduardo Castro-Nallar (3) , Youping Deng (4) , Christelle Desnues (5) , Emmanuel Dias-Neto (6) , Eran Elhaik (7) , Gregorio Iraola (8) , Soojin Jang (9) , Paweł Łabaj (10) , Christopher Mason (1) , Niranjan Nagarajan (11) , Michael Poulsen (12) , Bharath Prithiviraj (13) , Rania Siam (14) , Tieliu Shi (15) , Haruo Suzuki (16) , Johannes Werner (17) , Maria Mercedes Zambrano (18) , Malay Bhattacharyya (19)

1 Weill Cornell Medicine [New York]
2 INSP - National Institute of Public Health = Instituto Nacional de Salud Pública [Cuernavaca, Mexique]
3 UNAB - Universidad Andrés Bello [Santiago]
4 UH - University of Hawai'i [Honolulu]
5 MIO - Institut méditerranéen d'océanologie
6 USP - Universidade de São Paulo = University of São Paulo
7 Lund University [Lund]
8 Institut Pasteur de Montevideo
9 Institut Pasteur Korea - Institut Pasteur de Corée
10 UJ - Uniwersytet Jagielloński w Krakowie = Jagiellonian University
11 NUS - National University of Singapore
12 UCPH - University of Copenhagen = Københavns Universitet
13 CUNY - City University of New York [New York]
14 American University in Cairo
15 ECNU - East China Normal University [Shangaï]
16 Keio University
17 University of Tübingen
18 Corporación Corpogen and Universidad Central
19 Indian Statistical Institute [Kolkata]

Domains: Life Sciences [q-bio]; Life Sciences [q-bio]; Human health and pathology; Emerging diseases; Life Sciences [q-bio]; Santé publique et épidémiologie

Ebrahim Afshinnekoo, Chandrima Bhattacharya, Ana Burguete-García, Eduardo Castro-Nallar, Youping Deng, et al.. COVID-19 drug practices risk antimicrobial resistance evolution. The Lancet Microbe, 2021, ⟨10.1016/S2666-5247(21)00039-2⟩. ⟨hal-03160391⟩